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Abstract Tobacco smoking causes cardiovascular, respiratory and malignant dis-
ease, and stopping smoking is among the key medical interventions to lower
the worldwide burden of these disorders. However, the addictive properties of
cigarette smoking, including nicotine inhalation, render most quit attempts
unsuccessful. Recommended therapies, including combinations of counsel-
ling and medication, produce long-term continuous abstinence rates of no
more than 30%. Thus, more effective treatment options are needed.
An intriguing novel therapeutic concept is vaccination against nicotine. The
basic principle of this approach is that, after entering the systemic circulation, a
substantial proportion of nicotine can be bound by antibodies. Once bound to
antibodies, nicotine is no longer able to cross the blood-brain barrier. As a
consequence, the rewarding effects of nicotine are diminished, and relapse to
smoking is less likely to occur. Animal studies indicate that antibodies pro-
foundly change the pharmacokinetics of the drug and can interfere with nicotine
self-administration and impact on the severity of withdrawal symptoms. To date,
five phase I/II clinical trials using vaccines against nicotine have been published.
Results have been disappointing in that an increase in quit rates was only ob-
served in small groups of smokers displaying particularly high antibody titres.
The failure of encouraging preclinical data to completely translate to
clinical studies may be partially explained by shortcomings of animal models
of addiction and an incomplete understanding of the complex physiological
and behavioural processes contributing to tobacco addiction. This review
summarizes the current status of research and suggests some directions for
the future development of vaccines against nicotine. Ideally, these vaccines
could one day become part of a multifaceted approach to treating tobacco
addiction that includes counselling and pharmacotherapy.
1. Introduction
There are currently 1 billion tobacco smokers in
the world,[1] at least half of whom will eventually
die from a smoking-related disease.[2] By causing
cardiovascular, respiratory and malignant disease,
smoking accounts for 10% of global mortality.[3]
Due to its pharmacokinetic properties, nicotine
that is inhaled from cigarette smoke readily evokes
addiction in many smokers (see Benowitz[4] for
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details). Accordingly, tobacco dependence has
been called a chronic disease necessitating specific
treatment.[5] The treatment of tobacco use usually
involves some form of counselling[6] or pharma-
cotherapy;[7] ideally, both approaches should be
combined.[8] Currently available pharmacother-
apy increases quit rates by reducing craving or
providing relief from withdrawal symptoms.
Recent research regarding drugs to support quit
attempts has focussed on combination therapies,[9]
pharmacogenetics[10] andmodifications to existing
dosing regimens.[11,12] However, long-term con-
tinuous abstinence rates achieved by approved
treatment options, combined with intensive coun-
selling, rarely exceed 30%,[8] and patient adherence
to treatment is modest.[13] As smokers display
diverse smoking patterns[14] and different needs
when trying to quit, increased diversity of treat-
ment options would be desirable.[15] An intriguing
novel concept is nicotine vaccination. The basic
principle of this approach is that, after entering
the systemic circulation, a substantial proportion
of nicotine can be bound by antibodies. Once
bound to antibodies, nicotine is no longer able to
cross the blood-brain barrier. As a consequence,
the rewarding effects of nicotine are diminished,
and relapse to smoking is less likely to occur.[16]
Preclinical experiments have yielded promising
results, and, to date, five reports of phase I–II
trials using nicotine vaccines in humans have been
published.[17-21]
Starting from a summary of neural mechan-
isms involved in nicotine addiction, this review
illustrates some practical aspects relevant to the
design of a nicotine vaccine. An overview of
principle findings from animal studies is followed
by a more detailed description of clinical trial
results. The article concludes with a critical ap-
praisal of this novel therapeutic approach and
some suggestions for future research.
2. Mechanisms of Nicotine Addiction
2.1 Nicotine Pharmacokinetics
Nicotine is part of the particulate phase of
tobacco smoke and constitutes the most pre-
valent alkaloid in tobacco. It is a small molecule
(162 daltons). As indicated by its chemical name,
(S)-3-(1-Methylpyrrolidin-2-yl)pyridine, this nat-
ural insecticide contains a pyridine and a pyrroli-
dine ring, both of which are carrying a tertiary
amine. The two rings possess different acid dis-
sociation constants, producing a net acid dis-
sociation constant (pKa) of 8.0–8.5 (for overview,
please see Hukkanen et al.[22]). The acidity of
cigarette smoke (pH= 5.5–6.0) prevents large doses
of nicotine from being absorbed by the oral
mucosa.However, in themore alkaline environment
of the pulmonary alveoli (pH 7.4), one in three nic-
otine molecules is non-ionized and thus capable of
crossing biological membranes. The average nico-
tine content of a cigarette is 10–14mg,[23] only 10%
of which enters the systemic circulation,[24] resulting
in peak plasma concentrations of 300–500nM.[25]
Nicotine intake from one cigarette is approximately
0.015mg per kg,[24] and this dose has been used in
most preclinical studies using nicotine infusions in
animals.
The amount of nicotine binding to plasma pro-
teins is negligible (5%[26]); its half-life is 2 hours,[27]
and the greater part of nicotine is metabolized to
cotinine. This conversion is almost exclusively ca-
talyzed by one specific cytochrome P450 (CYP)
isoenzyme (CYP2A6).[28] The rate of nicotine me-
tabolism is determined by genetic[29] and hormon-
al[30] factors as well as concomitant medication and
appears to have a direct impact on the severity of
withdrawal symptoms and, ultimately, the success
of a quit attempt.[31,32]
2.2 Nicotine Effects on the Brain
While most pathophysiological mechanisms
underlying smoking-related disease are activated
by smoke constituents other than nicotine, it has
been known for several decades that nicotine ef-
fects on the brain following smoke inhalation are
central to the addictive properties of smoking.[33]
In the broadest sense, nicotine impacts on loco-
motion, cognition, affect, pain sensitivity[34] and
arousal.[35] Most importantly, however, nicotine
increases the brain’s responsiveness to rewarding
stimuli,[36] ultimately leading to addiction. Nico-
tine delivery kinetics to the brain appear to be
crucial in facilitating this effect in that a rapid
e2 Raupach et al.
ª 2012 Raupach et al., publisher and licensee Adis Data Information BV. Drugs 2012; 72 (4)
increase in nicotine levels is much more likely to
promote self-administration (a laboratory para-
digm for addiction) than slow kinetics.[37,38] In
humans, high levels of nicotine reach the brain
within 10–20 seconds after taking a puff from a
cigarette.[39] In fact, most smokers report that the
subjective effects of cigarette smoking aremaximal
in the first few minutes after smoke inhalation.[40]
This has led to the assumption that nicotine effects
on the brain are primarily determined by the speed
at which the compound enters the brain.[41]
Various in vivo and in vitro studies performed
in the mid-1980s have identified the mesocorti-
colimbic dopamine system as the primary site
of action regarding nicotine’s reinforcing and
rewarding effects.[42] This complex neuronal net-
work involves dopaminergic neurons located in
the ventral tegmental area (VTA) projecting to
diverse brain regions, including the nucleus ac-
cumbens (synonyms: NAcc, ventral striatum[43]).
Nicotine activates nicotinic acetylcholine recep-
tors (nAChR)[44,45] on VTA neurons, ultimately
leading to dopamine release in the NAcc.[46] In-
creased dopamine levels in this region generally
promote the development of drug dependence.[47,48]
Notwithstanding the need for a better under-
standing of the complex interactions of neuronal
pathways leading to addiction, reward from smok-
ing is likely to occur as a consequence of dopamine
release in the NAcc following a rapid increase in
brain nicotine concentration.
In addition to triggering dopamine release,
nicotine induces desensitization of nAChRs and
an increase in receptor density.[49] Receptor up-
regulation implies the possibility of developing a
hypercholinergic state when nicotine supply is
interrupted. In fact, regular smokers display an
almost complete receptor saturation,[50] which
may serve to prevent the occurrence of with-
drawal symptoms.
2.3 Nicotine Withdrawal and Relapse to
Smoking
Considering the pathophysiological basis of
nicotine addiction outlined in section 2.2, the re-
warding effects of peaking nicotine levels in the
brain would appear to be the main drivers of
nicotine addiction. However, animal research
suggests that the reinforcing potential of nicotine
is only moderate compared with other drugs of
abuse.[51] As a consequence, pending nicotine
withdrawal has been suggested to underlie con-
tinued smoking behaviour. Withdrawal can be
defined as a syndrome of behavioural, affective,
cognitive and physiological symptoms,[52] includ-
ing depressedmood, anxiety, irritability and crav-
ing.[53] Animal research shows that spontaneous
nicotine withdrawal results in a significant de-
crease in brain reward function.[51] Conversely,
dependent smokers may use nicotine inhalations
as a self-medication to relieve negative affect and
other withdrawal symptoms.[54] However, there
is no uniform clinical picture of withdrawal:[55] in
one study,[56] three patient clusters with distinct
characteristics of the syndrome were identified,
highlighting the difficulties associated with de-
veloping treatments to relieve withdrawal.
Symptoms of nicotine withdrawal may act as
triggers causing a smoking lapse during a quit
attempt. However, other trigger factors have also
been reported. Since smoking is a conditioned
behaviour,[57] cues associated with smoking can
urge patients to abandon their plans of quit-
ting.[4] Likewise, consumption of coffee and
alcohol,[58] specific social situations, negative feel-
ings and times of being alone are all associated
with an increased risk of experiencing a smoking
lapse.[59] Particularly early lapses (occurring within
the first 2 weeks of a quit attempt) are associated
with low long-term success rates.[60] Progression
from lapse to full-blown relapse only occurs if
smoking is perceived as rewarding. Thus, further
developments in pharmacotherapy for smoking
cessation should focus on reducing the rewarding
effects of smoking.
3. Vaccine Development: Rationale and
Practical Aspects
3.1 Working Mechanism of a Nicotine
Vaccine
Based on the assumptions that a rapid increase
in brain nicotine levels induces feelings of reward
and that quit attempts frequently fail due to early
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lapses, preventing nicotine from entering the
brain constitutes an intriguing concept. The idea
of using antibodies to bind a drug and thus dis-
abling it from crossing the blood-brain barrier
was first tested in an animal model of heroin ad-
diction[61,62] and subsequently extended to other
species and other drugs of abuse, including mor-
phine, methamphetamine, phencyclidine,[63] co-
caine[64] and nicotine.[65] To date, only nicotine and
cocaine have been used as vaccination targets in
human studies.[63] The term ‘vaccination’ (syno-
nym: active immunization) refers to the adminis-
tration of an immunogenic substrate that causes
T and B cell activation, leading to the formation of
specific antibodies within the studied individual.
By virtue of imprinting this response to the im-
munological memory, this approach yields longer-
lasting protection. However, therapeutic antibody
levels are only established several weeks after the
first vaccine injection. Passive immunization is de-
fined as the administration of preformed mono-
clonal or polyclonal high-affinity antibodies. This
strategy offers immediate protection. However, in
addition to being more expensive owing to high
manufacturing costs, its effects are more short
lived due to rapid degradation of antibodies.[66]
Moreover, the amount of injectable antibodies
is limited.[67] Studies in animals have used both
approaches, while clinical trials have focused on
active immunization procedures.
3.2 Characteristics of an Immune Response
The minimum molecular weight for a molecule
to elicit a specific immune response is 10kDa.[67]
Due to its small molecular weight, nicotine itself is
not immunogenic; in order to trigger an immune
response, nicotine or a structurally similar hapten
needs to be linked to a carrier protein,[68,69] thus
producing a conjugate vaccine. The success of an
immunological strategy relies on several char-
acteristics, including but not limited to (i) immu-
nogenicity of the vaccine; (ii) affinity of antibodies;
and (iii) specificity of antibodies.
3.2.1 Immunogenicity
Immunogenicity is assessed by the antibody
titre elicited by a vaccine. Titres (as measured by
ELISA) of >1 : 10.000 indicate satisfactory immu-
nogenicity.[70] Unfortunately, published reports of
vaccination studies have used different measures
of immunogenicity (ELISA titres,[17] geometric
mean titres,[18] absolute antibody concentrations,[71]
molar antibody concentrations,[19] ratio of specific
and total IgG concentrations[72]), thus complicating
the comparison of results between studies. In gen-
eral, immunogenicity is influenced by the choice of
the carrier protein and adjuvants added to the
vaccine.
3.2.2 Affinity
The primary measure of antibody affinity to
the target drug is the equilibrium dissociation
constant Kd, i.e. the ratio of unbound to bound
molecules at given concentrations.[63] High Kd
values indicate low affinity as large amounts of
unboundmolecules are needed to induce formation
of complexes between nicotine and its antibodies.
High affinity is desired in order to ascertain fast
clearance of unbound nicotine from the plasma;
however, extremely high affinity may be dis-
advantageous as saturation of all antibodies can be
achieved after one single nicotine dose, thus
compromising efficacy for subsequent nicotine
doses.[73] Total binding capacity of the serum is
influenced by both immunogenicity and affi-
nity.[63,74] Thus, lower affinity can be compen-
sated for by increasing antibody dose.[73]
3.2.3 Specificity
This term refers to the extent to which the
elicited antibodies bind to nicotine with high
specificity in preference to other molecules, in-
dicating low cross-reactivity between the anti-
body and nicotine metabolites such as cotinine,
nicotine-N-oxide and nornicotine.[74] High spe-
cificity is particularly important if these metabo-
lites occur in higher concentrations than the drug
itself, as is the case for cotinine. Cross-reactivity
can be reduced by exposing nicotine’s pyrrolidine
ring to the immune system as this ring is first
metabolized and thus not contained in most
nicotine derivatives.[74] At the same time, cross
reactivity might be desired if drug metabolites are
themselves pharmacologically active, as is the
case for cotinine[75-77] and nornicotine.[78] This
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has practical implications for the design of con-
jugate vaccines. For example, one recent study
showed that using longer rather than shorter link-
ers and attaching them to the 6- rather than the
5-position of the pyridine ring (i.e. further away
from the prime site of nicotine metabolism[79]) in-
creases antibody selectivity for nicotine.[74]
4. Preclinical Studies
4.1 Objectives of Animal Studies
Antibodies binding a drug will primarily change
its pharmacokinetic profile[63] which, in the case of
nicotine, should abolish the functionally critical
brain concentration peak, making nicotine intake
less rewarding.[66] Accordingly, the primary objec-
tives of preclinical studies were to study the effects
of nicotine antibodies on (i) pharmacokinetics
(serum and brain nicotine concentrations follow-
ing acute and chronic administration of the drug;
nicotine half-life in serum); (ii) brain function and
behaviour (dopamine release in the NAcc, nicotine
self-administration); and (iii) signs of withdrawal.
4.2 Methodology
A comprehensive description of the experi-
mental procedures used to model addiction in an-
imals is beyond the scope of this review (see LeSage
et al.[66] for details). Both passive and active im-
munization approaches have been used to study
the effects of nicotine antibodies in animals, and
the vast majority of research was done on rats.
Passive immunization was usually performed by
intravenous[80] or (rarely) intraperitoneal[81] appli-
cation of antibodies. Most studies used the nico-
tine-specific monoclonal antibody Nic311 with a
Kd value of 60nM.
[73] Vaccination involved the
singular or repeated intraperitoneal administration
of an immunogen;[70,71,82] however, subcutaneous
and intranasal vaccine delivery has also been re-
ported.[83] Themajority of vaccination studies were
done with one of the following:
 6-(carboxymethylureido)-(6)-nicotine (CMUNic)
linked to keyhole limpet hemocyanin (KLH)[84]
 3-aminomethyl-nicotine (30-AmNic) linked to
Pseudomonas aeruginosa exoprotein A (rEPA)[65]
 the nicotine derivate IP18 linked to KLH[85]
 nicotine coupled to virus-like particles formed
by the coat protein of the bacteriophage Qb.[19]
In order to produce a satisfactory immune
response, these vaccines need to be combined
with an adjuvant. The synthesis of a further im-
munogenic compound has been reported in the
literature. This peptide-based vaccine containing
a residue of an agonist of human complement
factor C5a does not require the simultaneous
administration of an adjuvant. To date, only one
experimental study using this vaccine has been
published.[86]
4.3 Principal Findings
This section describes principal findings from
animal studies of passive immunization and vacci-
nation against nicotine (table I). Following a brief
discussion of antibody properties reported in the
literature, the three primary objectives mentioned
in section 4.1 will be addressed.
4.3.1 Antibody Characteristics Following
Vaccination
Following repeated vaccination with CMU-
Nic-KLH[84,88] or 30-AmNic-rEPA,[65,82] antibody
titres as determined by ELISA were greater than
1 : 10 000, and antibody concentration ranged
from 100mg/mL[84] to 300mg/mL.[71] Four injec-
tions of 30-Am-Nic-rEPA elicited titres between
1 : 200 000 and 1 : 250 000,[70] comparable to those
produced by two injections of IP18-KLH.[96]
In one experiment, antibody concentrations fol-
lowing simultaneous bivalent vaccination with
30-AmNic-rEPA and 6-CMUNic-KLH were great-
er than those elicited by monovalent vaccination.[98]
Notably, antibody formation did not appear to be
impeded by the presence of nicotine during the
vaccination procedure.[82]
The dissociation constant Kd of antibodies was
within the range of 10–30nM,[98] and nicotine
binding capacity was approximately 2· 10-6M
(equivalent to 210– 110ng/mL). Nicotine-specific
IgG represented approximately 1–2% of total
IgG.[65,84,88]
Antibodies yielded high specificity for nico-
tine,[65,85,87] with only minor cross-reactivity to
major metabolites of the drug.[19,74,83]
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4.3.2 Pharmacokinetics
Binding of nicotine to antibodies is expected to
result in greater retention of the drug in the serum.
Accordingly, serum nicotine concentrations fol-
lowing acute administration were increased at least
6-fold in both passively immunized and vaccinated
rats as compared with controls.[65] The increase
was slightly smaller in vaccinated rats receiving
five nicotine injections over a period of 80 minutes,
simulating repeated exposure as present in smok-
ers.[88] Despite increased total nicotine levels, the
fraction of unbound (and thus active) drug was
reduced by up to 92%[89] as evidenced by atten-
uated cardiovascular effects in passively im-
munized animals[65] and the absence of seizures in
vaccinated rats that would normally be observed
following high-dose nicotine infusion.[99] Since
nicotine binding partially protects the drug from
being metabolized, plasma half-life of nicotine was
increased 2.2- to 8-fold by passive immunization[73]
and vaccination,[88] respectively.
As outlined in previous sections, the primary aim
of binding nicotine in the serum is to prevent the
drug from entering the brain. In most preclinical
experiments, brain nicotine concentration was
measured shortly (i.e. 3 minutes) after a nicotine
bolus injection. Results varied significantly between
studies: following acute administration, passive im-
munization decreased brain levels of nicotine by
30%[65] to 90%[80] comparedwith controls; similarly,
variable reductions were observed in vaccinated
rats[65,71,82,83,87,89,90] receiving a single nicotine bolus.
In vaccinated rats, reductions in brain nicotine
concentration were greatest shortly after acute ad-
ministration of nicotine.[89] Interestingly, regardless
of the mode of immunization, reductions in brain
nicotine levels were considerably smaller following
the chronic administration of nicotine.[65,71,82,88,89,91]
Table I. Effects of passive immunization and vaccination against nicotine on pharmacokinetics, brain function and behaviour and withdrawal
in animal studies
Parameter Passive immunization Vaccination
Pharmacokinetics
Serum/plasma nicotine concentration following acute
nicotine administration
Increased 6- to 18-fold[65] Increased 6-[84,87] to 8.5-fold[65]
Serum/plasma nicotine concentration following chronic
nicotine administration
Increased 6-fold[65] Increased 2- to 4-fold[88]
Brain nicotine concentration following acute nicotine
administration
Reduced by 30%,[65] 40%,[80]
80%[73] or 90%[80]
Unchanged[84] or reduced by 35–40%,[87]
50–60%[65,82,89,90] or 90%[71,83]
Brain nicotine concentration following chronic nicotine
administration
Unchanged[91] or reduced by
13%[65]
Reduced by 30%[71,82,88,89]
Serum nicotine half-life Increased 2.2-fold[73] Increased 8-fold[88]
Brain function and behaviour
Increase of dopamine release in the nucleus accumbens
following acute nicotine administration
Abolished[85]




Acquisition of nicotine self-administration Reduced (not significant)[70]
Maintenance of nicotine self-administration Reduced[70]
Nicotine intake in a self-administration setting Increased[94]




Withdrawal signs in the presence of nicotine Unchanged[80] Unchanged[96]
Withdrawal signs in the absence of nicotine Reduced[97] Reduced[96]
Reduction of withdrawal signs following acute nicotine
administration
Attenuated[81] Reduced[96]
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Effects of immunization on nicotine pharma-
cokinetics were dose dependent in that higher
antibody concentrations elicited more profound
nicotine retention in serum and a larger decrease
in brain nicotine concentration.[65,73,80]
4.3.3 Brain Function and Behaviour
An acute increase of dopamine output in the
NAcc following nicotine administration is believed
to mediate the addictive properties of smoking. In
vaccinated rats, this increase was abolished.[85]
Likewise, the increase in locomotor activity follow-
ing acute nicotine exposure was attenuated in both
vaccinated[92] and passively immunized[65] animals,
and the combination of both approaches further
increased this effect.[100,101] Moreover, in the pres-
ence of antibodies, rats were less able to discrimi-
nate nicotine from saline injections.[93] The effect of
vaccination on the development and maintenance
of nicotine addiction was studied in experiments
using rats that were trained to self-administer nico-
tine[102] at clinically relevant doses (0.01–0.06mg/kg
per dose, eliciting a [nicotine]plasma of 10–60 ng/
mL[103]). While the acquisition of nicotine self-
administration was not significantly impeded by
the vaccine, maintenance of this learned behaviour
was attenuated. One study found no evidence of
compensatory overdosing aimed at surmounting
the effects of vaccination,[70] while the results of
another more recent study reported increased nic-
otine intake following vaccination. This might
have been due to lower antibody concentrations
and higher doses of nicotine infusions in the latter
study, resulting in saturation of antibody binding
sites and, consequently, insufficient sequestering
of the drug.[94]
Even more importantly, vaccination abolished
the reinstatement of nicotine self-administration
following extinction of the conditioned response
and re-exposure to nicotine, simulating a smok-
ing lapse.[95] This effect was dependent on high
antibody levels and was more pronounced with
smaller priming doses of nicotine, resembling in-
take from one-tenth of a cigarette.[95]
4.3.4 Withdrawal
Due to a lack of effect on brain nAChRs, im-
munization against nicotine is unlikely tomodulate
withdrawal symptoms. On the contrary, it may be
hypothesized that immunization during smoking
might induce withdrawal as newly formed anti-
bodies abolish brain nicotine peaks, which are
essential for feelings of reward to occur. Assess-
ment of nicotine withdrawal symptoms in an
animal model of addiction is difficult. However,
the available data suggest that neither passive
immunization[80] nor vaccination[96] precipitate
withdrawal in the presence of nicotine.Moreover,
withdrawal following the termination of nicotine
administration was reduced in immunized rats as
compared with controls,[96] although there was
evidence of persisting nicotine dependence.[97] Fi-
nally, one study investigated the effects of passive
immunization on the reduction of withdrawal
signs following re-exposure to nicotine.[81] In the
presence of antibodies against nicotine, with-
drawal relief achieved by nicotine administration
was attenuated. Similar findings were reported
following vaccination.[96]
4.4 Summary of Findings from Animal Studies
Vaccination of rats produced antibodies with
high affinity and specificity for nicotine. One en-
couraging finding regarding the possibility of
vaccinating active smokers was that immuno-
genicity of the vaccine was not impaired by the
presence of nicotine. Animal studies have con-
firmed the hypothesis that nicotine pharmaco-
kinetics are markedly changed in the presence of
antibodies against nicotine. Effects on serum and
brain concentrations of the drug were dependent
on antibody concentration, greatest shortly after
the application of a single nicotine dose and more
pronounced when smaller priming doses were
used. While vaccination may prevent acute nico-
tine delivery to the brain, chronic accumulation
of the drug in the brain was only moderately af-
fected by the presence of antibodies, i.e. nicotine
entry into the brain was delayed rather than fully
prevented. Accordingly, acute nicotine effects in do-
pamine release in the NAcc and related behaviours
were attenuated in vaccinated animals. However,
vaccination did not interfere with the development
of nicotine addiction in a self-administration para-
digm, and, even with favourable antibody titres,
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maintenance of nicotine self-administration was
not affected by vaccination in some animals.[70]
The attenuation of withdrawal severity observed in
vaccinated animalsmight be explained by prolonged
nicotine half-life in the presence of antibodies. The
finding of reduced alleviation of withdrawal symp-
toms by a priming dose of nicotine in vaccinated
rats suggests that nicotine vaccination might be
most effective in preventing relapse in smokers
trying to quit.[66,67,104]
5. Clinical Studies
At least four vaccines against nicotine are cur-
rently under clinical development,[74] but peer-
reviewed reports have only been published for two
of them:
1. NicVAX[18,20,21] contains 30-AmNic linked to
rEPA. This vaccine was developed by Nabi
Pharmaceuticals and is currently being further
evaluated for clinical use by GlaxoSmithKline.
2. NIC002 (synonym: NicotineQb[17,19]) contains
a nicotine derivative coupled to a virus-like particle
formed by the coat protein of the bacteriophage
Qb in Escherichia coli. This vaccine was developed
byCytos Biotechnology; further clinical evaluation
is being carried out by Novartis.
All published clinical trials used alum as an
adjuvant to boost immune responses. Additional
vaccines currently being tested are TA-NIC
(containing recombinant cholera toxin B; devel-
oped by Celtic Pharma/Xenova[105]) and Niccine
(developed by Pharmaceutica AB[74]), and at least
two further companies are currently evaluating
nicotine vaccines at the preclinical stage with no
published reports available at the time of data
collection for this review. A summary of prelim-
inary results published on company websites can
be found elsewhere.[106]
Results of the five published reports of phase I/II
studies are summarized in table II. In the following
section, principal results regarding safety, immuno-
genicity and efficacy are reviewed.
5.1 Study Design
Three studies (two using NicVAX[18,20] and
one using NIC002[19]) were primarily designed to
assess safety and immunogenicity and therefore
included smaller groups of non-smokers or smok-
ers not intending to quit; cessation counselling
was not offered in these studies. Two more recent
trials also assessing efficacy included smokers
willing to quit.[17,21] In these studies, subjects
were required to set a quit date following their
second vaccination, and cessation counselling
was provided. The comparability of results is
impaired by the fact that counselling was only
provided in two out of five trials. Studies differed
regarding vaccine doses used and vaccination
schemes (for details see table II).
5.2 Safety
Mild to moderate local reactions at injection
sites (ache and tenderness) were common in all
studies. Systemic reactions, which were also mild
in most cases, included myalgia, malaise and
headaches. The prevalence of these symptoms
was similar in participants receiving a vaccine
and those receiving adjuvant without the active
vaccine, indicating that adverse events were not
related to the vaccine itself.[20,21] Serious adverse
events potentially related to treatment were
rarely observed: one subject with a history of al-
lergy to penicillin was reported to have suffered
from an anaphylactic reaction 70 minutes after
receiving the first 400 mg dose of NicVAX.[21]
5.3 Immunogenicity
The immune response to nicotine vaccination
was highly variable in all five trials. As a common
feature, higher vaccine doses elicited stronger re-
sponses, and antibody titres tended to peak fol-
lowing the final injection although this was not
observed in all studies.[20] Comparison of immu-
nogenicity across trials is complicated as some
studies reported geometric mean titres, while
others assessed ELISA titres. The maximum an-
tibody concentration in the most recent proof-of-
concept study was 45 mg/mL.[21] By including
both smokers and non-smokers, one study dem-
onstrated that immunogenicity was not impeded
by the presence of nicotine.[18] Antibody affinity
to nicotine was only assessed in one trial using
NIC002; the Kd value was 33 nM. Data on anti-
e8 Raupach et al.
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body specificity following vaccination in humans
have not been published.
5.4 Efficacy
Three trials reported data on smoking sta-
tus.[17,20,21] Following vaccination, there was no
evidence of compensatory smoking in order to
overcome the effects of antibodies blocking nicotine
entry into the brain. At the same time, vaccination
did not appear to induce withdrawal symptoms in
smokers.
The first study formally assessing continuous
abstinence rates was published in 2008.[17] Ac-
cording to the intent-to-treat analysis, there was
no significant difference between 3-month con-
tinuous abstinence rates until month 6 between
the intervention and control groups (30.1% vs
26.1%). However, a per-protocol analysis ex-
cluding all subjects with concomitant use of nic-
otine replacement therapy revealed significantly
higher abstinence rates in the upper third of re-
sponders (i.e. subjects with particularly high an-
tibody titres) as compared with the placebo group
(56.6% vs 31.3%; odds ratio [OR] 2.9, 95%CI 1.4,
5.9; p = 0.004). This difference was maintained
until 12 months (41.5% vs 21.3%; OR 2.6, 95%CI
1.2, 5.7; p = 0.012).
Based on these results, a subsequent trial was
intended to further establish a relationship be-
tween antibody titres and smoking outcome.[21]
Continuous abstinence rates at 12 months were
significantly higher in the top 30% responders
than in subjects receiving placebo (19.7% vs 6.0%;
OR 4.41, 95% CI 1.53, 12.71; p= 0.006). In addi-
tion, continuous abstinence was enhanced in sub-
jects receiving the most intensive vaccination
regimen. Finally, among smokers who failed to quit,
smoking reduction occurred more frequently in
subjects with high antibody titres (‘responders’)
compared with placebo.
Recently NABI Biopharmaceuticals announced
the results of the first phase III, double-blinded,
placebo-controlled trial including 1000 subjects
who received a total of six vaccinations with Nic-
VAX 400mg or placebo. A preliminary assessment
of the trial data showed that continuous abstinence
for 16 weeks, from week 37 to 52, was similar in
both treatment arms and approximately 11%.[107]
However, a peer-reviewed report of these results
has not been published yet.
5.5 Summary of Findings from Phase I/II Trials
Taken together, published results of phase I/II
studies indicate that nicotine vaccination is well
tolerated and capable of inducing an immune re-
sponse against nicotine even with concomitant
smoking. However, in contrast to expectations
from animal studies, vaccination failed to increase
continuous abstinence rates over placebo.
6. Strengths and Limitations; Suggestions
for Future Research
The basic idea of preventing nicotine from
entering the brain, thereby blocking its rewarding
effects in the mesolimbic system is attractive as
antibodies are unlikely to elicit adverse effects
within the brain[67] that have been described for
other smoking-cessation medications.[108,109] In
fact, no major adverse events following vaccina-
tion were reported in phase I/II clinical trials.
A further advantage of this novel approach is that
treatment adherence is likely to be favourable[110]
as vaccination requires only a limited number of
injections and no daily dosing. Clinical trials have
partially confirmed preclinical observations (e.g.
lack of compensatory smoking), but they failed to
establish a clear effect of vaccination on smoking
behaviour.
Knowledge of the reasons for this failure of the
vaccination concept to successfully translate to the
clinical setting is crucial for the future development
of nicotine vaccines. One obvious limitation of
phase I/II trials was that they were not designed to
assess efficacy endpoints. Moreover, the propor-
tion of subjects receiving all scheduled vaccinations
was as low as 60% in one trial.[21] Choosing a target
quit date shortly after the first booster injection
might also have impaired efficacy, as peak antibody
titres were only observed following several vacci-
nations. In addition, as nicotine-binding capacity is
not only determined by antibody concentration, a
more thorough investigation of antibody affinity
and specificity in these trials would have been de-
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sirable. However, some issues going beyond these
practical aspects need to be addressed in order to
understand the obvious discrepancy between pre-
clinical and clinical findings.
6.1 Tobacco Addiction
Recent research into the pathophysiology of
drug dependence indicates that viewing nicotine
peaks and subsequent dopamine release in the
NAcc as an indispensable element of tobacco
addiction may be too simplistic. Thus, dopami-
nergic VTA neurons have been found to increase
their activity not only in response to nicotine but
also in the presence of aversive stimuli,[111] and
animal studies suggest that hedonic responses can
be elicited in the absence of dopamine.[112] The
finding of increased smoking-cessation rates fol-
lowing damage to the insula[113] further sub-
stantiates the notion that the mesolimbic reward
circuit is but one brain structure relevant to
nicotine addiction. Finally, the whole concept of
nicotine concentration peaks underlying the re-
warding effects of smoking has been questioned
by a positron emission tomography (PET) study
suggesting a gradual increase in brain nicotine
levels during smoking with no evidence of con-
centration peaks following each puff.[114]
Until recently,[115] the non-nicotinic compon-
ents of tobacco addiction[116] have received rela-
tively little scientific attention. It is now recognized
that tobacco addiction results from an interplay of
pharmacological, psychological, genetic and en-
vironmental factors.[4] The contribution of nicotine
to this complex interaction may be smaller than
previously thought[117] as rewards elicited by
smoking can also be induced by smoking denico-
tinized cigarettes.[118] In fact, substances in smoke
other than nicotine have been found to enhance the
reinforcing properties of nicotine.[119] Among
these, acetaldehyde[120] and agents blocking mono-
amine oxidase activity[121] may play a major role.
Results of animal experiments indicate that nicotine
and other agents might support early conditioning
of the reward response triggered by smoking-
related cues. At a later stage, these conditioned
stimuli might be sufficient to generate feelings of
reward.[122]
6.2 Limitations of Animal Models
At first glance, preclinical studies provide
convincing evidence that a nicotine vaccine is
likely to reduce nicotine self-administration[70]
and possibly even attenuate withdrawal symp-
toms,[96] thus facilitating smoking cessation and
preventing relapse. However, although great ef-
forts were made to adjust nicotine concentrations
in animals to those observed in smokers,[123] the
extent to which these findings can be applied to
tobacco addiction in humans remains unclear.
First, much of this evidence relates to serum and
brain nicotine concentrationsmeasured shortly after
the intravenous application of nicotine (table I).
Most animal models did not use nicotine inhala-
tion as the primary route of drug administration.
In addition, these experiments have not assessed
temporal patterns of nicotine distribution to dif-
ferent organs including the brain[114] and the
lungs.[71,89,114] The clinical significance of reduc-
ing nicotine distribution to the brain by 40–60%
at one fixed time-point is unclear[82] as it is the
persistence of nicotine in the brain that appears to
modulate structure and function of nAChRs.[4]
Second, the immune response elicited by vacci-
nation against nicotine may differ from species to
species. Accordingly, antibody levels reported in rats
ranged from 100mg/mL[84] to 300mg/mL,[71] while
much lower concentrations (up to 45mg/mL[21]) were
observed in clinical trials. Yet, this difference might
be attributable to the heterogeneousmethodology in
determining antibody levels.
Third, as the rewarding properties of nicotine are
limited,[51] preclinical research paradigms focusing
on reinforcement[102] may not be sufficient to model
the complex pharmacological and behavioural as-
pects of smoking and cessation. In fact, animal
studies have rarely used the cues and psychosocial
processes associated with relapse.[124] Even when
cues were used,[95] the validity of experimental ex-
tinction of these conditioned stimuli to mirror quit
attempts in humans is highly debatable.
6.3 Clinical Trial Design
As an introduction of nicotine vaccines to in-
ternational markets will depend on the results of
future trials, these studies need to be carefully
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designed. Despite the conclusion drawn from pre-
clinical studies that a nicotine vaccine might be
primarily useful in preventing relapse, published
clinical trials were designed as smoking-cessation
studies including target quit dates. They mainly
assessed continuous abstinence rather than with-
drawal severity, the incidence of lapses and their
progression to full relapse.[125] Variables that are
known to impact on continuous abstinence, in-
cluding the speed of nicotine metabolism,[126-130]
have not been investigated in vaccination studies.
In addition, antibody characteristics, including af-
finity and specificity, clearly have a huge impact on
functionality[74] and thus require thorough evalua-
tion in clinical trials. Careful selection of primary
study endpoints and secondary measurements is
therefore warranted for these trials, and study po-
pulations must be aligned to these endpoints.
Smokers who have already quit may represent
an ideal target group for a relapse prevention study.
However, the formation of sufficient amounts of
antibodies takes at least 6 weeks, while most relapse
occurs within the first 2 weeks of a quit attempt.[131]
As a consequence, subjects would have to be en-
rolledwell before quitting, whichmay be difficult as
50% of quit attempts occur spontaneously.[132] Ac-
cordingly, offering nicotine vaccination to smokers
willing to reduce their cigarette consumption with
the ultimate goal of quitting could be a viable op-
tion. Once these smokers feel prepared to quit,
adequate antibody levels might be readily available.
Finally, monotherapy with a nicotine vaccine
does not appear to be a promising tool to over-
come the complex physiological and psychosocial
alterations observed in smokers. Thus, a nicotine
vaccine with sufficient efficacy could one day
become part of a multifaceted intervention[104]
that includes behavioural as well as pharma-
cological approaches. Regarding the latter, var-
enicline might be used in combination with the
vaccine as it produces high abstinence rates at the
end of treatment,[133] after which relapse needs to
be prevented. A 1-year study combining vareni-
cline with placebo-controlled NicVAX focussing
on relapse prevention in almost 600 smokers is
underway and may help to unravel a possible
synergism between these drugs. The utility of nic-
otine replacement therapy, bupropion and novel
agents such as cytisine[134,135] in this setting also
needs to be established. Finally, smokers who
decide to quit spontaneously and seek immediate
help might be offered passive immunization fol-
lowed by pharmacotherapy to reduce craving and
withdrawal symptoms while vaccination is start-
ed concomitantly in order to establish adequate
antibody titres to prevent relapse at a later stage.
7. Conclusions
Vaccination against nicotine is an intriguing
novel therapeutic approach to treating nicotine
addiction.[136] By preventing nicotine from en-
tering into the brain, antibodies might abolish the
rewarding properties of smoking. Animal studies
indicate that antibodies profoundly change the
pharmacokinetics of the drug and can interfere
with nicotine self-administration. However, in re-
cent phase I/II trials and one unpublished phase III
trial, these findings were not fully replicated. In
addition to assessing alternative routes of vaccine
administration[137,138] and addressing ethical is-
sues generally associated with vaccinations against
drugs of abuse,[139,140] future studies will need to
more clearly define the ideal indications and tar-
get populations for nicotine vaccines. Treatment
of dependent smokers cannot be reduced to a
course of vaccine injections but needs to acknowl-
edge the complex pharmacological and behavioural
aspects of smoking.
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